132 related articles for article (PubMed ID: 37209451)
1. Discovery of thiohydantoin based antagonists of androgen receptor with efficient degradation for the treatment of prostate cancer.
Chang X; Zhang D; Qu F; Xie Y; Chen T; Zhang Y; Du Q; Bian J; Li Z; Wang J; Xu X
Eur J Med Chem; 2023 Sep; 257():115490. PubMed ID: 37209451
[TBL] [Abstract][Full Text] [Related]
2. Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.
Xu X; Ge R; Li L; Wang J; Lu X; Xue S; Chen X; Li Z; Bian J
Eur J Med Chem; 2018 Jan; 143():1325-1344. PubMed ID: 29117897
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.
Wang A; Wang Y; Meng X; Yang Y
Bioorg Med Chem; 2021 Feb; 31():115953. PubMed ID: 33388655
[TBL] [Abstract][Full Text] [Related]
4. Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
Xu X; Du Q; Meng Y; Li Z; Wu H; Li Y; Zhao Z; Ge R; Lu X; Xue S; Chen X; Yang Y; Wang J; Bian J
Eur J Med Chem; 2020 Apr; 192():112196. PubMed ID: 32169785
[TBL] [Abstract][Full Text] [Related]
5. Novel selective agents for the degradation of AR/AR-V7 to treat advanced prostate cancer.
Yang Y; Lv G; Xiu R; Yang H; Wang W; Yu P; Zhang J; Ye L; Wang H; Tian J
Eur J Med Chem; 2024 May; 271():116400. PubMed ID: 38626524
[TBL] [Abstract][Full Text] [Related]
6. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
7. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1
Chen C; Chai X; Hu X; Lou S; Li D; Hou T; Cui S
J Med Chem; 2022 Oct; 65(19):13074-13093. PubMed ID: 36154033
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
[TBL] [Abstract][Full Text] [Related]
12. Discovery of
Zhang B; Liu C; Yang Z; Zhang S; Hu X; Li B; Mao M; Wang X; Li Z; Ma S; Zhang S; Qin C
J Med Chem; 2023 Aug; 66(16):11158-11186. PubMed ID: 37556600
[TBL] [Abstract][Full Text] [Related]
13. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.
Han X; Wang C; Qin C; Xiang W; Fernandez-Salas E; Yang CY; Wang M; Zhao L; Xu T; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
J Med Chem; 2019 Jan; 62(2):941-964. PubMed ID: 30629437
[TBL] [Abstract][Full Text] [Related]
14. A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.
Auvin S; Öztürk H; Abaci YT; Mautino G; Meyer-Losic F; Jollivet F; Bashir T; de Thé H; Sahin U
Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31431473
[TBL] [Abstract][Full Text] [Related]
15. Prostate fibroblasts enhance androgen receptor splice variant 7 expression in prostate cancer cells.
Sasaki T; Yoshikawa Y; Kageyama T; Sugino Y; Kato M; Masui S; Nishikawa K; Inoue T
Prostate; 2023 Mar; 83(4):364-375. PubMed ID: 36479717
[TBL] [Abstract][Full Text] [Related]
16. Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy.
Quick J; Santos ND; Cheng MHY; Chander N; Brimacombe CA; Kulkarni J; van der Meel R; Tam YYC; Witzigmann D; Cullis PR
J Control Release; 2022 Sep; 349():174-183. PubMed ID: 35780952
[TBL] [Abstract][Full Text] [Related]
17. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of indoline thiohydantoin derivatives based on enzalutamide as antiproliferative agents against prostate cancer.
Zuo M; Xu X; Xie Z; Ge R; Zhang Z; Li Z; Bian J
Eur J Med Chem; 2017 Jan; 125():1002-1022. PubMed ID: 27810589
[TBL] [Abstract][Full Text] [Related]
19. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
20. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.
Singh P; Hallur G; Anchoori RK; Bakare O; Kageyama Y; Khan SR; Isaacs JT
Prostate; 2008 Oct; 68(14):1570-81. PubMed ID: 18668523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
